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Background: The absence of commercialized vaccines and antiviral agents against dengue has made the disease a
major health concern around the world. With the current dengue virus transmission rate and incidences, the
development of antiviral drugs is of vital need. The aim of this project was to evaluate the possibility of developing
a local medicinal plant, Phyllanthus as an anti-dengue agent.
Methods: Cocktail (aqueous and methanolic) extracts were prepared from four species of Phyllanthus (P.amarus,
P.niruri, P.urinaria, and P.watsonii) and their polyphenolic compounds were identified via HPLC and LC-MS/MS
analysis. MTS assay was then carried out to determine the maximal non-toxic dose (MNTD) of the extracts, followed
by screening of the in vitro antiviral activity of aqueous cocktail extracts against DENV2 by means of time-of
-addition (pre-, simultaneous and post-) using RT-qPCR. The differentially expressed proteins in the treated and
infected cells were analysed with two dimensional gel electrophoresis experiments.
Results: Several active compounds including gallic acid, geraniin, syringin, and corilagen have been identified. The
MNTD of both aqueous and methanolic extracts on Vero cells were 250.0 μg/ml and 15.63 μg/ml respectively.
Phyllanthus showed strongest inhibitory activity against DENV2 with more than 90% of virus reduction in
simultaneous treatment. Two-dimensional analysis revealed significantly altered levels of thirteen proteins, which
were successfully identified by tandem MS (MS/MS). These altered proteins were involved in several biological
processes, including viral entry, viral transcription and translation regulations, cytoskeletal assembly, and cellular
metabolisms.
Conclusions: Phyllanthus could be potentially developed as an anti-DENV agent.
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Dengue virus (DENV), of the family Flaviviridae, is the
causative agent for the high morbidity rated disease-
dengue. Being a tropical/sub-tropical disease, dengue is
currently endemic in more than 100 countries around
the world. It is estimated that 36 million dengue fever
cases and another 2.1 million cases of severe dengue
occur yearly [1]. These numbers are predicted to in-
crease over the years, mainly due to global warming and* Correspondence: shamalamy@yahoo.com
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reproduction in any medium, provided the orthe increased frequencies of migration, local and inter-
national travelling [2] as this arthropod-borne virus is
mainly transmitted by mosquitoes, Aedes aegypti and
Aedes albopictus.
DENV is a single-stranded positive sense RNA virus
with a genome of approximately 11 kb [3] which en-
codes for 3 structural proteins (capsid (C), envelope (E)
and membrane (M)) and 7 non-structural (NS) proteins
(NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5). Des-
pite extensive research on dengue, many ambiguities lie
in the functions on the various DENV proteins. Never-
theless, the NS3 protein has been shown to be multi-
functional with protease activity at its N-terminal. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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triphosphatase, and RNA 5′-triphosphatase at its C-
terminal [3,4], while, the N-terminal of NS5 represents a
methyltransferase and its C-terminal a RNA-dependent
RNA polymerase. NS1, on the other hand, has been
suggested to play a role in endothelium dysfunction in
dengue [5].
Traditionally classified as dengue fever (DF), dengue
haemorrhagic fever (DHF) and dengue shock syndrome
(DSS), at present, the disease classification has been re-
vised [6] into dengue with/without warning signs and se-
vere dengue. The usual symptoms of dengue include
fever, nausea, rashes, whereas the warning signs for the
disease includes abdominal pain, persistent vomiting,
mucosal bleeding, hepatomegaly and increased levels of
hematocrit concurrent with the decreased levels of plate-
lets. Patients who suffer from severe plasma leakage,
haemorrhage and organ impairment have higher mortal-
ity rates, if not managed well clinically. A primary infec-
tion of dengue confers life-long protection towards that
particular serotype, not towards the other 3 DENV sero-
types [2]. This particularly complicates secondary infec-
tions, where antibody enhancement [7] and cross-
reactive memory T cell activation [8] are postulated to
cause more severe manifestations of dengue. To date,
there are neither effective anti-dengue agents nor com-
mercially licensed vaccines for the treatment of dengue
[9,10]. The current methods of controlling dengue are
mosquito eradication programs [11] and fluid manage-
ment therapy for infected individuals [6]. Therefore, the
need for new antiviral agents is imperative for early
treatment to prevent manifestation of severe dengue, to
curb outbreaks and in the future to complement possible
vaccination programs.
Plants have always been an exclusive part in traditional
healing, and in the past decades as treatment sources for
various diseases, due to their complex bioactive ingredi-
ents and rich source of pharmaceuticals [12]. Plants have
been revealed to offer better sources of antiviral agents
compared to synthetic analogues [13], which has since
prompted identification of more than 3800 plants with
efficient abilities to suppress the growth of numerous vi-
ruses [14]. These include Olea eurolaea leaf extract
which demonstrated strong antiviral activity towards hu-
man immunodeficiency virus (HIV) type 1 [15] and in-
fluenza virus [16], Rozites caperata which acts against
herpes simplex virus (HSV) types 1 and 2 [12], Sargas-
sum patens acting against HSV type 1 [17], as well as
Phyllanthus nanus, Salvia miltiorrhiza, Radix astragala,
and Rheum palmatum which have anti-hepatitis B virus
effect [18]. The most intriguing fact of using plant
sources as antiviral agents, lies in the fact that these
plants are usually found in abundance in developing
and third world countries, where infectious diseasesoccur are more rampant. One such plant genus is the
Phyllanthus (Euphorbiaceae), which has around 750
species [19] and is distributed throughout the tropical
and subtropical countries (which are also where dengue
occurs). Phyllanthus is well known for its pharmaco-
logical properties in folk medicine [20] as well as in
modern treatments of kidney and liver diseases, urinary
bladder and intestinal infections; diabetes, hepatitis, dys-
entery, jaundice, gonorrhea and skin ulcers [20,21]. The
plant has also been proposed to show anti-cancer activ-
ities [22,23].
With tremendous potential as pharmacological sources,
we seek to evaluate the antiviral potential of Phyllanthus
cocktail extracts which is a mixture of four Phyllanthus
species, namely P. urinaria, P. niruri, P. amarus, and P.
watsonii in vitro against dengue virus type 2 (DENV2) as
well as to determine its possible pharmacological activity.
Methods
Cocktail extract preparation
The cocktail (aqueous and methanolic) extracts consisting
of four different pooled Phyllanthus species (P.amarus,
P.niruri, P.urinaria, and P.watsonii) were kindly prepared
and provided by the Biotechnology Centre, Malaysian Agri-
cultural & Research Development Institute (MARDI). All
four species of Phyllanthus were grown in greenhouse from
year January 2008 till December 2010 under controlled irri-
gation and fertilization at MARDI and the samples were
harvested every two months since March 2008. The plant
species were identified based on taxonomical identification
by Dr Salma Idris, a taxonomist from Strategic Research
Centre, MARDI and the herbarium specimen is kept at
MARDI, Serdang. Each of the species contains different
chemical profiles in terms of the type of phytochemicals
and their amount. Hence, a cocktail Phyllanthus extract
was prepared from P.watsonii, P. amarus, P. niruri, and P.
urinaria in the ratio of 2:2:1:1 respectively, as we wanted to
obtain a wide range of phytochemicals that will eventually
hit multiple disease targets. We hope that the synergistic
effects of the various phytochemical from the four species
will be able to be more effective in challenging the disease
through its multiple targets.
Briefly, whole plant samples (minus roots) were freshly
harvested, washed and dried at room temperature. The
samples were cut into smaller pieces and ground with li-
quid nitrogen into powder and finally freeze dried. For
aqueous extract, freeze-dried powder was extracted with
20 mL of water, 20 mM of diethyldithiocarbamic acid
and 0.5% formic acid, whereas, absolute methanol was
used for methanolic extract preparation. The samples
were subjected to homogenization and filtered with 15
Whatman No. 40. The extracts were stored at −20°C
until use and a single batch of extracts was used for all
the experiments.
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liquid chromatography (HPLC) and mass spectrometry
(LC-MS-MS) analysis
Proteins were identified using HPLC and LC-MS-MS as
previously described by Tang and colleagues [22]. For
the aqueous cocktail extract, 2 ml of supernatant was
concentrated by vacuum evaporator, followed by re-
dissolving in 20 mg/ml with 30% methanol and then
subjected to LC-MS-MS. While for the methanolic ex-
tract, supernatant was subjected to rotary evaporation
(Rotavapor RII, BUCHI, Switzerland) and re-dissolved
with 20% methanol. The sample was then separated
using solid phase extraction (SPE) column (LiChrolut
RP-18 1000 mg/6 ml, Merck Germany) with the mobile
phase of 60% and 70% methanol. The collected elutes
were then concentrated to a volume of 0.5 ml, then di-
luted eight times with 40% methanol, and finally
subjected to LC-MS-MS analysis.
The separation of both extracts was carried out using
HPLC binary pump, an autosampler injector compart-
ment and a diode array detector (DAD) (1200 Series,
Agilent Technologies, Germany). The reverse phase used
was C-18, 150 mm X 4.6 mm i.d. 5 μm particle size of
Thermo Hypersil GOLD column (Thermo Scientific,
UK), while the composition of mobile phase used was
0.1% formic acid in water (solvent A) and 0.1% formic
acid in acetonitrile (solvent B) with gradient for solvent
B: 5% (5 min), 5-90% (60 min), 5% (4 min) at a flow rate
of 1 ml/min. Total volume of injection was 20 μl and
the detection was assigned at 280 nm and 360 nm. For
mass spectrometry analysis, 3200 QTrap LC/MS/MS
system (Applied Bioscience – MDS Sciex) was utilized.
For negative ionization, the iron source was set at 500°C
and voltage maintained at −4.5 kV. The nitrogen gener-
ator was operated at 60 curtain gas flow, 90 psi source
gas flow and 60 psi exhaust gas flow. Two scanning
modes were used; enhance mass spectrometer (EMS)
and enhance ion product (EPI) for a full scan mass spec-
tra ranging m/z 100–1200.
Virus and cell culture
The New Guinea C (GeneBank Accession No. M29095)
strain of DENV2 was obtained from the Department of
Medical Microbiology, University of Malaya and used
throughout the study. The virus was cultured and propa-
gated in Aedes albopictus mosquito cell line C6/36
(ATCC: CRL-1660) with Leibowitz-15 (L-15) medium
containing 1% heat-inactivated foetal bovine serum (FBS.
Gibco) at 30°C. The supernatant from infected C6/36
cells was collected for viral titre determination as well as
for subsequent experimental applications. The porcine
kidney (PS) cell line was maintained in L-15 media
containing 5% FBS at 30°C and the African green mon-
key kidney cells (Vero) (ATCC: CCR-81) were culturedin DMEM supplemented with 10% FBS at 37°C. Cells
were maintained in humidified air with 5% CO2. Cells
undergoing exponential growth were used throughout
the experiments.
Virus titration
The PS cells were seeded at a cell density of 1.5 × 105
per well in 24-well plates (Nunc, Denmark). Ten-fold
serial dilutions of viral supernatant were prepared in L-
15 medium containing 1% FBS, and loaded on the cells.
After 3 hours, 3% carboxylmethyl cellulose (Calbiochem,
USA) containing 3% FBS in L-15 was added into each
well and further incubated for 3–4 days. After 3–4 days
of incubation, the cells were washed with PBS, and
stained with 1% of naphthalene blue, followed by visual
counting of plaques.
Determination of maximum non-toxic dose (MNTD)
Prior to screening of Phyllanthus cocktail extracts for
their antiviral properties, they were first subjected to
cytotoxicity assay to identify the maximal non-toxic dose
(MNTD) on Vero cells. The MNTD is a concentration
where it does not show any toxicity effects on cell viabil-
ity. Briefly, 1 × 104 Vero cells were seeded into each well
of a 96-well flat-bottom plate and incubated overnight
for attachment. After 24 hours, different concentrations
of extracts ranging from 15.63-500 μg/ml were added
into respective wells in triplicates and further incubated
for different time points (24, 48 and 72 hours). Control
wells contained cells with culture medium without the
extracts and negative control wells contained only cul-
ture medium with different concentrations of the ex-
tracts. After each time course of study, 100 μl of
supernatant was discarded and 20 μl of MTS/PMS solu-
tion (Promega, USA) was added, followed by incubation
in the dark for 1 hour. Absorbance was measured using
GloMax (Promega, USA) at 490 nm with a reference
wavelength of 600 nm. Absorbance is directly propor-
tional to the number of live cells in the culture. Thus,
the dose–response graph was presented in percentage of
Vero cell’s viability against different concentration of
extracts.
In vitro antiviral experiment
Three different modes of treatment were performed to
study the in vitro antiviral activity of Phyllanthus. For
pre-treatment mode, Vero cells were seeded in a 24-well
plate and incubated overnight for attachment. Before
virus inoculation, the MNTD of Phyllanthus extract was
added to the cells and incubated for 24 h. DENV2 was
inoculated at an MOI of 0.1 onto the Phyllanthus-
treated Vero cells. For the simultaneous treatment,
Phyllanthus extract and DENV2 (MOI: 0.1) were pre-
pared and then inoculated onto near confluent Vero cell
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0.1) were inoculated onto the cells and incubated for
24 h. After 24 hour, the medium was removed and re-
placed by the Phyllanthus extract. Subsequently for all
treatment modes, the cultures were further incubated
for 24, 48 and 72 h at 37°C under 5% CO2 atmosphere.
After each time point of study, supernatants as well as
cells were collected separately subsequent to 2 cycles of
freeze-thawing and were then stored at −80°C for ensu-
ing experiments.
RNA isolation and real-time RT-PCR
Real time RT-PCR was performed to detect and quanti-
tate viral RNA in infected Vero cells treated with
Phyllanthus extract. RNA was extracted from samples
(supernatant and cells) according to the instructions
provided by AccuPrep viral RNA extraction Kit (Bioneer,
Korea) and the extracted RNA was then stored at −80°C
until further use. Dengue virus standard curve was pre-
pared using MAXIscript Transcription Kit (Ambion,
USA). Ten-fold serially diluted RNA was prepared and
subjected to real-time RT-PCR. The copy number of
RNA was calculated based on the concentration mea-
sured and its molecular weight. RT-PCR was carried out
using iScriptTM One Step RT-PCR Kit with SYBR Green
(Bio-Rad, USA), employing dengue group specific
primers with adaption of SYBR green technology [24].
The 25 μl reaction mixture containing 5 μl of sample
RNA, 0.25 μl of each primers, 0.25 μl of reverse tran-
scriptase enzyme, 12.5 μl of SYBR Green mix and water,
was amplified in a CFX96 RT-PCR machine (Bio-Rad,
USA). The thermal profile for the one-step SYBR Green-
based RT-PCRs consisted of a 1 hour RT step at 45°C,
followed by 35 cycles of 3 steps amplification at 95°C for
30 seconds, 60°C for 30 seconds and 72 for 30 seconds.
Fluorescence data were collected during the extension
step. Negative and positive controls were included in
each analytical run.
Two-dimensional (2D) gel electrophoresis
Equal amounts of total protein from (i) cells only,
(ii) Phyllanthus-treated cells, (iii) DENV2- infected
cells, and (iv) Phyllanthus treated-infected cells, were
subjected to 2D gel electrophoresis according to the
manufacturer’s instructions (GE Healthcare). Briefly,
total proteins were extracted from control and experi-
mental samples by incubation with lysis buffer on ice for
30 minutes. The protein pellets were re-solubilized in re-
hydration solution (8 M urea, 2% CHAPS, 40 mM DTT,
0.5% IPG buffer pH3-11NL, bromophenol blue) and
kept at −80°C until further analysis. Total amount of
proteins was determined using 2D Quant kit (GE
Healthcare) and 250 μg of proteins were rehydrated into
13 cm immobilized pH gradient (IPG) strips (pH 3–11nonlinear) (GE Healthcare). The first dimension was
electrophoresed on the IPGphor III machine (GE
Healthcare) at 20°C with the following settings: step 1 at
500 V for 1 hour; step 2 at 500-1000 V for 1 hour; step 3
at 1000-8000 V for 2.5 hour, and step 4 at 8000 V for
0.5 h. Once first dimensional separation was completed,
the gel was equilibrated as follows; first reduction with
64.8 mM of dithiothreitol-SDS equilibration buffer
(50 mM Tris–HCl [pH 8.8], 6 M urea, 30% glycerol, 2%
SDS, 0.002% bromophenol blue) for 15 minutes,
followed by alkylation with 135.2 mM of iodoacetamide-
SDS equilibration buffer for another 15 minutes. The
second dimension electrophoresis was carried out using
the SE600 Ruby system (GE Healthcare) at 25°C in an
electrode buffer (25 mM Tris, 192 mM glycine, and 0.1%
[wt/vol] SDS) with the following settings: step 1 at
100 V/gel for 45 minutes; step 2 at 300 V/gel until the
run is completed. The gels used in the second dimension
were 12.5% homogenous acrylamide gels casted in the
laboratory. After electrophoresis, the gels were fixed
with destaining solution for 30 minutes, followed by
staining with hot Coomasie blue for 10 minutes. The
gels were scanned using Ettan DIGE Imager (GE
Healthcare). Gel images were analyzed using PDQuest
2-D Analysis Software (Bio-Rad, USA) and only protein
spots which showed significant differences (more than
1.5 fold) were selected for mass spectrometry analysis.
Protein digestion and desalting and MALDI-TOF/TOF
analysis
Protein spots excised from polyacrylamide gels were
kept in sterile 1.5 ml tubes and sent to Proteomics
International Pty Ltd, Australia for further analysis.
Briefly, the protein samples were first digested with
mass spectrometry grade typsin and the peptides were
extracted according to standard techniques . Peptides
were analyzed by MALDI-TOF/TOF mass spectrom-
eter using a 5800 Proteomics Analyzer [AB Sciex].
Identification of proteins was performed by using Mas-
cot sequence matching software [Matrix Science] with
Uniprot database.
Data analysis
Results were expressed as the mean ± standard error
mean (SEM) of data obtained from triplicate experi-
ments. All data were analyzed using one way ANOVA,
followed by Dunnett’s test for pairwise comparison. P <
0.05 was considered statistically significant for all tests.
All analysis was performed using SPSS software.
Results
Identification of polyphenol compounds in Phyllanthus
The phytochemicals contained in all Phyllanthus species
were first optimally separated using HPLC and then
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cocktail extract, different Phyllanthus species were
mixed at specific proportions to obtain the highest
amounts of health benefiting phytochemicals. The mixed
cocktail extracts were analysed using both HPLC and
LC-MS-MS where a variety of polyphenol compounds
were identified (Figure 1). These compounds include
gallic acid, galloylglucopyronside, corilagen, geraniin,
rutin, quercetin glucoside, syringing, syringing diamer,
digalloylglucopyronside, trigalloylglucopyronside, apigenin
rhamnoside, and quercetin rhamnoside. Their individual
percentages in both the aqueous and methanolic extracts
are shown in Table 1 and among this compounds, geraniin
constitutes the greatest amount in both the extracts, in
particular in the methanolic extract.
Cytotoxicity activity of aqueous and methanolic extracts
of Phyllanthus
From the cytotoxicity study using the Vero cell line, we
noted that the MNTD for aqueous and methanolic
extracts were 250 μg/ml and 15.63 μg/ml, respectivelyFigure 1 Separation of polyphenolic compounds from Phyllanthus co(Figures 2A and 2B). The aqueous cocktail extract of
Phyllanthus showed lower toxicity to Vero cells as com-
pared to the methanolic extract as its cell viability
remained above 90% when treated up to 250 μg/ml.
Thus, only the aqueous cocktail extract of Phyllanthus
was selected for further antiviral studies.
In vitro antiviral activity of Phyllanthus
Via real time RT-qPCR, the in vitro antiviral activities of
aqueous Phyllanthus cocktail on DENV2 were assessed
in 3 different treatment modes (Figure 3, Additional
file 1). Comparing the three different modes of treat-
ment, Phyllanthus showed the strongest antiviral activity
against DENV2 during the simultaneous mode of treat-
ment with more than 83 - 95% reduction of virus inhib-
ition (Table 2). The morphological alterations of Vero
cells due to virus replication were completely prevented
when 250 μg/ml of the extract was added into the
infected cultures. On the other hand, the virus reduction
was not pronounced in pre-treatment as compared to
simultaneous treatment, with only 5 - 46% virus inhibitioncktail by reverse-phase HPLC.
Table 1 Percentages of individual polyphenolic compound in aqueous and methanolic extracts
Location of compounds found in chromatogram Compound % present in water extract % present in methanolic extract
1 Gallic acid 0.0004 0.032
2 Galloylglucopyronside 0.0003 Not detected
3 Syringin 0.0005 Not detected
4 Syringin diamer 0.0005 Not detected
5 Digalloylglucopyronside 0.0002 0.019
6 Trigalloylglucopyronside 0.0003 0.020
7 Corilagen 0.0008 0.084
8 Apigenin rhamnoside <0.0002 Not detected
9 Geraniin 3.237 17.140
10 Rutin 0.015 0.012
11 Quercetin glucoside 0.021 0.016
12 Quercetin rhamnoside <0.0002 Not detected
Figure 2 Percentage of Vero cells viability at different times of incubation and dosages of Phyllanthus treatments. (A) Vero cells treated
with aqueous cocktail extract of Phyllanthus and (B) Vero cells treated with methanolic cocktail extract of Phyllanthus. Results are expressed as
mean ± SEM of three independent experiments. * signifies p < 0.05 compared to the untreated control.
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Figure 3 In-vitro antiviral assay via SYBR-Green RT-PCR. (A) Melt peak of DENV2. (B) Representative amplification plot for DENV2 antiviral
assay. (C) Standard curve for DENV2.
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reduction with post-infection treatment with Phyllanthus
extracts.
Proteome analysis of DENV2 infected cells with or without
Phyllanthus treatment
To determine the actual antiviral mechanisms of
Phyllanthus against DENV2 protein profiling of
Phyllanthus-treated dengue-infected cells via 2D gelTable 2 Percent Inhibition of virus copy number in cell and su




C + V 0 0 0
C + P + V 6.38 ± 5.59 46.07 ± 0.88* 4.66 ± 6.3
SIMULTANEOUS TREATMENT
C + V 0 0 0
C + P + V 94.69 ± 0.40* 82.85 ± 3.91* 92.78 ± 0.
POST-TREATMENT
C + V 0 0 0
C + P + V 0 0 0
Results are expressed as mean ± SEM of three independent experiments. C + V = d
cells. * signifies p < 0.05.electrophoresis was carried out. This was compared to
three other different protein profiles including cells only,
Phyllanthus-treated cells and dengue-infected cells.
A total of 52 proteins were found to be differentially
expressed (Figure 4), but only 24 proteins were deemed
significant (protein scores > 55) after mass spectrometry
analysis. Fourteen proteins which had significantly al-
tered expression were identified, where some of these
proteins are represented by more than one protein spotpernatant at three different treatment modes
us copy number (%)
48 Hour 72 Hour
Supernatant Cell Supernatant
0 0 0
3 39.01 ± 5.01* 0 17.87 ± 4.89*
0 0 0
83* 84.61 ± 6.58* 93.61 ± 1.38* 91.48 ± 3.66*
0 0 0
0 0 0
engue-infected cells; and C + P + V = Phyllanthus treated-dengue infected
Figure 4 Proteome analysis of DENV2 infected cells with or without Phyllanthus treatment. (A) Cells Only, (B) Phyllanthus-treated cells, (C)
DENV2 Infected cells and (D) Phyllanthus treated infected cells.
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70 kDA protein,, Beta actin, Hepatocyte growth factor
receptor, DNA topoisomerase I, NS3, G3PD (Glyceralde-
hyde-3-phosphate dehydrogenase), RBM1 (RNA-binding
motif 1), Histidine triad nucleotide-binding protein 1,
DNA mismatch repair protein Msh2, Chain B, Dengue
virus NS2bNS3, and Polysialyltransferase. These proteins
consist of host cell proteins as well as viral proteins that
are involved in various biological processes, including
viral entry and replication, molecular chaperoning, cyto-
skeletal assembly, and cellular metabolisms (Table 3;
Figure 5).
Discussion
Since the discovery of Phyllanthus and its anti-hepatitis
B viral effect in the late 1980s [25], the plant Phyllanthus
has been tested for its various pharmacological effects.
Various species of this plant genus have exhibited activ-
ities that range from being anti-hepatotoxic [26,27], anti-
viral [25,28], antibacterial [29,30], anti-diabetic [31,32] to
having anti-tumour and anti-carcinogenic effects [22,23].
Here, we assess the effectiveness of Phyllanthus against
DENV which has become a global menace especially inthe lack of commercialized vaccines and anti-DENV
agents.
Two different Phyllanthus cocktail of different extrac-
tion method was tested initially for their toxicity against
Vero cells in vitro. The aqueous cocktail displayed lower
cytotoxicity even up to the concentration of 250 μg/ml
and was thus selected for subsequent experimental
procedures. The Phyllanthus cocktail had various bio-
active compounds which included gallic acid, geraniin,
syringing and corilage (Figure 1) [22,23] and these com-
ponents are believed to behave synergistically to display
the anti-DENV activity observed in this study. Neverthe-
less, the percentages of geraniin in the extracts were
the highest and hence were predicted to exert most
of the antiviral effect. Yang et al. (2007) had demon-
strated the suppression of herpes simplex viruses 1 and
2 by geraniin isolated from Phyllanthus urinaria [33].
Besides that, geraniin was also demonstrated to inhibit
enterovirus 71 replication in both in vitro and in vivo
[34]. These studies therefore accentuate the potential
of Phyllanthus cocktail to act as an agent that suppresses
dengue virus infection due to its presence of high
geraniin content.
Table 3 Differential protein levels in Phyllanthus-treated dengue-infected Vero cells
ID Accession Score Possible proteins C C + P C + V C + V + P
Viral Entry
3 Q28222.1 1059 Heat Shock Protein 70 (Hsp70) 192.1 200.2 312.2 234.3
4 Q28222.1 768 Heat Shock Protein 70 (Hsp 70) 199.5 287.4 419.3 282.2
5 Q2IBA6.1 483 Hepatocyte Growth Factor Receptor (HGFR) 192.7 200.4 313.4 259.7
12 Q2IBA6.1 136 Hepatocyte Growth Factor Receptor (HGFR) 222.5 0.0 313.2 218.2
14 Q2IBA6.1 178 Hepatocyte Growth Factor Receptor (HGFR) 206.3 0.0 312.5 200.1
22 Q2IBA6.1 139 Hepatocyte Growth Factor Receptor (HGFR) 231.9 237.1 331.3 225.5
39 Q2IBA6.1 132 Hepatocyte Growth Factor Receptor (HGFR) 203.8 206.7 390.0 212.9
41 Q2IBA6.1 120 Hepatocyte Growth Factor Receptor (HGFR) 211.0 224.2 333.2 221.6
Viral Uncoating
37 AAT48107.1 132 Trim 1 187.4 198.8 366.1 535.3
Viral Transcription and Translation
7 ABB92440.1 489 RNA Binding Motif 1 (RBMI) 197.6 0.0 412.3 222.2
8 ABB92440.1 383 RNA Binding Motif 1 (RBMI) 206.0 0.0 362.1 226.7
10 ABB92440.1 141 RNA Binding Motif 1 (RBMI) 213.8 0.0 372.7 221.2
24 ABB92440.1 77 RNA Binding Motif 1 (RBMI) 180.4 0.0 362.4 181.7
42 ABB92440.1 633 RNA Binding Motif 1 (RBMI) 202.9 222.2 424.2 313.3
27 NP_739587.2 173 Nonstructural protein NS3 0.0 0.0 312.3 123.2
35 2FOM_B 151 Chain B, Dengue virus NS2bNS3 Protease 0.0 0.0 262.8 123.2
38 Q7YR26.1 63 DNA topoisomerase 1 (DNA Topo 1) 202.9 211.3 373.2 229.2
43 Q5XXB5.1 84 DNA mismatch repair protein Msh2 201.1 212.2 415.2 311.3
44 Q5XXB5.1 129 DNA mismatch repair protein Msh2 209.1 205.3 394.2 213.3
47 Q5RF69 185 Histidine triad nucleotide-binding protein 1 194.4 189.1 393.4 194.0
Viral Post-translational Modification
25 Q4VIT5.1 346 Calreticulin 188.0 200.4 333.3 213.2
Glucose Uptake and Glycolytic Enzymes
6 Q8CGV6 559 Glyceraldehyde-3-phosphate dehydrogenase (G3PD) 213.9 231.3 524.1 313.2
49 AAF17105.1 151 Polysialyltransferase 207.1 212.3 313.7 232.3
Cytoskeletal assembly
1 Q76N69.1 846 Beta actin 168.8 185.3 512.2 273.2
C = cells only; C + P = Phyllanthus-treated cells; C + V = dengue-infected cells; C + P + V = Phyllanthus treated dengue infected cells.
Lee et al. BMC Complementary and Alternative Medicine 2013, 13:192 Page 9 of 13
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viral attachment; (2) viral entry; (3) membrane fusion;
(4) RNA release; (5) viral protein production; (6) RNA
replication; (7) viral assembly; (8) viral transport and
maturation and lastly (9) viral release. Hence, the anti-
DENV assessment of the aqueous Phyllanthus was done
in a time-of-addition manner and we noted that the ex-
tract exhibited the most activity in the simultaneous
assay, which was then followed by the pre-treatment
assay. This implied that the Phyllanthus extract may be
blocking viral adsorption into the Vero cells [35]. On the
other hand, post-treatment of Vero cells following
DENV infection showed minimal antiviral effects, indi-
cating that it possibly had lower effect on the late repli-
cation stage of DENV RNA replication. Therefore, wepostulated that firstly Phyllanthus could possibly be
altering/blocking the virus or host factors [36] by hin-
dering viral entry into the host cells. Secondly, this in-
hibition could also be partly due to the ability of some
bioactive components in the extract which can directly
inactivate DENV particles [37].
In order to obtain a clearer picture behind the anti-
DENV of Phyllanthus aqueous cocktail, we performed
a protein profiling assay to study protein alterations
in Phyllanthus treated DENV infected Vero cells. Of
the many differentially expressed proteins observed, 13
different proteins were significantly noted to play roles
in DENV reduction. As postulated, several of the pro-
teins differentially expressed were noted to play roles
in viral adsorption and entry. Host cell receptors for
Figure 5 Schematic diagram showing possible mechanism of dengue virus inhibition by Phyllanthus. (A) Viral entry; (B) Viral endocytosis,
membrane fusion, necleocapsid release; (C) Glucose uptake; (D) Viral pre replication and RNA replication; (E) Viral production and proteolytic
processing; and (F) Viral assembly and maturation.
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cells and DC-SIGN on macrophages and monocytes.
The monocytic cells also consist of Hsp70 and Hsp90
which are important components of the lipid raft in the
DENV entry receptor complex [38,39]. The expression
of Hsp70 was decreased in the Phyllanthus treated-
DENV infected cells, indicating that viral attachment
and entry via this particular receptor complex has been
thwarted (Figure 5A). The Hsp70 has also been known
to interact with LOX1 receptor to initiate cytotoxic T
lymphocytes (CTL) response [40]. A reduction of Hsp70
by Phyllanthus could prevent activation of cross-reactive
memory T cells in a secondary infection, a hypothesized
mechanism behind dengue immunopathogenesis.
The hepatocytes are target cells in DENV2 infections [41]
and the hepatocyte growth factor (HGF) is a mitogen for
hepatocytes [42]. The HGF receptor (HGFR) has been im-
plied as a co-receptor for adeno-associated virus type 2infections [43], and although this has not been shown for
dengue virus entry, the HGF per se has been found to be
increased in the serum of dengue infected patients [44]. A
down-regulation of the HGFR was noted in the Phyllanthus
treated DENV2 infected cells indicating a possible role for
this receptor for virus entry into cells (Figure 5A).
The cytoskeleton is an important part of a cell and
one of its main components is the β-actin which was
found to be down-regulated by Phyllanthus in DENV2
infected cells (Figure 5B). Dengue viruses enter cells via
receptor-mediated endocytosis, form vesicles, undergo
membrane fusion and their necleocapsid released into
the cytoplasm. These movements are mediated by the
actin skeleton [45] and in a DENV2 infection study, the
actin skeleton has been shown to be an integral part for
viral entry, production as well as release. Therefore, here
we show that since Phyllanthus has shown inhibitory ef-
fects before and during DENV2 infection, it is clear that
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cells or the synthesis of viral polyproteins.
During a viral infection, glucose uptake and glycolytic
enzyme activity is usually increased for ATP production
[46], a major energy source for cells. The ATPs are ne-
cessary in a variety of ATP-dependent cellular processes
during viral replication [47] and they are usually cata-
lyzed by viral-encoded enzymes or complexes consisting
of viral and host-cell proteins. Among the many en-
zymes involved, two (glyceraldehyde-3-phosphate de-
hydrogenase (GAPDH) and polysialyltransferase) were
found to be down-regulated in Phyllanthus treated
DENV2 infected cells (Figure 5C). The GAPDH has also
been shown to co-localize with viral RNA-dependent
RNA polymerase (NS5) in JEV-infected cells [48] and
this may be reflected in DENV infection. The reduction
of GAPDH may therefore lead to the inhibition of repli-
cation and amplification of viral RNA. Meanwhile,
polysialyltransferase is an enzyme that polymerizes the
sugar into a polysaccharide form and a reduction of
these overexpressed enzymes in Phyllanthus-treated
infected cells may lead to a low production of ATP and
hence, a reduction in viral RNA replication. Generally, the
decrease of both these proteins imply that Phyllanthus
maybe preventing the virus from hijacking the host cell’s
glucose uptake and glycolytic enzymes (GAPDH and
polysialyltransferase enzyme) during viral replication.
Tripartite motif (TRIM) proteins are involved in diverse
cellular processes, such as cell proliferation, differenti-
ation, oncogenesis, and apoptosis [49]. The exact func-
tions of TRIMS during virus infection are still poorly
understood but TRIM1 has been shown to display anti-
viral activity against N-tropic murine leukaemia virus [50]
by inhibiting the pre-reverse transcription step, suggesting
a role for this particular protein against viral genome repli-
cation. Hence, it is possible that the high levels of TRIM1
protein detected in our Phyllanthus treated cells may have
halted the genome replication of DENV2 and thus
disrupted further viral propagation (Figure 5D).
Proteolytic processing of DENV polyprotein is an im-
portant step in viral replication and maturation. The
DENV NS3 is multifunctional with a serine protease at
its N-terminal, together with NS2B (NS2B/NS3 com-
plex) cleaves the viral polyprotein for the subsequent
viral assembly and maturation [51]. The dengue NS3
was detected at lower levels in Phyllanthus treated
infected cells, and this directly reduced the amount of
NS2B/NS3 pro complex formed as was observed in this
study (Figure 5E). This complex has been a major and
promising target for the development of anti-DENV
agents, and Phyllanthus has shown this potential by
inhibiting polyprotein processing.
Following polyprotein processing, viral budding occurs
in the endoplasmic reticulum (ER), where they formimmature virion and are then transported to the Golgi
complex. The human immunoglobulin binding heavy
chain protein, a HSP70 member and 2 ER chaperones,
calnexin and calreticulin have been found to be involved
in DENV E protein folding and assembly [52]. A reduc-
tion of both Hsp70 and calreticulin in our study after
treatment with Phyllanthus, indicates that this plant is
able to disrupt production of mature virions (Figure 5F).
Four other proteins were also detected to be down-
regulated by Phyllanthus in the DENV2 treated Vero
cells, including DNA topoisomerase I, RNA-binding
motif (RBM)-1, histidine triad nucleotide-binding pro-
tein 1, and DNA mismatch repair protein (Msh2). These
proteins’ functions have mainly revolved around the
DNA replication of host cells, and are still elusive in the
infection of DENV. Nevertheless, the Msh2 DNA mis-
match protein have been shown to be required for the
replication of HSV-1 and Epstein-Barr virus, where the
protein has been localized to the viral replication com-
partments [53,54]. The RBM-1 is also known as hetero-
geneous ribonuclearprotein (hnRNP)- G. Several protein
of the hnRNP family has been shown to up-regulated in
DENV2 infected endothelial cells [55]. Phyllanthus may
have been suppressing these proteins to inhibit viral rep-
lication; however this remains to be addressed.Conclusions
From our in-vitro experiments, we noted that Phyllanthus
does have antiviral activities against DENV2 and this was
further supported by differential regulation of various host
and viral proteins (Figure 5). We also propose that
Phyllanthus is an early inhibitor as it showed most anti-
DENV effect prior to infection or during infection. Our
suggestion is strengthened by the fact that the plant
targeted 13 differentially regulated proteins which were of
the cell-virus attachment, viral entry, viral polyprotein
production, viral RNA replication as well as viral assembly
and maturation. We envisage that the aqueous extract of
Phyllanthus has the potential to be a candidate in the de-
velopment of anti-dengue agents, however, additional
work involving the other DENV serotypes, in vivo (toxicity
and efficacy) and pre-clinical studies need to conducted
for this extract to be concluded as a good anti-viral agent.Additional file
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